NSE · Healthcare · Diagnostics & Research
EPS came in at 10.13 against a street estimate of 11.01 — a miss of 8.0%.
with an average price target of ₹2,013.46.
| Holder | Stake |
|---|---|
| HDFC Mutual Fund - HDFC Nifty Smallcap 250 ETF | 3.91% |
| Smallcap World Fund, Inc | 2.60% |
| Uti-flexi Cap Fund | 2.49% |
| Aditya Birla Sun Life Mutual Fund - Aditya Birla Sun Life Small Cap Fund | 2.19% |
| Nippon Life India Trustee Ltd-a/c Nippon India Nifty 500 Equal Weight Index Fund | 2.19% |
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 DR. LAL PATHLABS LIMITED – Q1 FY2027 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue: Rs 798 crore in Q1 FY27, up 19.1% YoY (Q1 FY26: Rs 670 crore) — hi | 2026-07-24 |
| Quarterly results · Q1 FY27 DR LAL PATHLABS LIMITED - Q1 FY27 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue: Rs 798 Cr with growth of 19.1% year-on-year • EBITDA: Rs 247 Cr with | 2026-07-24 |
| Annual report FY2026 DR. LAL PATHLABS LIMITED - FY 2025-26 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹27,629 million (12.2% YoY growth) • Reporte | 2026-07-01 |
| Q4 FY26 earnings call DR. LAL PATHLABS LIMITED - Q4 & FY26 EARNINGS SUMMARY HEADLINE NUMBERS • FY26 Revenue: Rs. 2,763 crore, growth of 12.2% (FY25: Rs. 2,461 crore) • Q4 | 2026-05-06 |
| Quarterly results · Q4 FY26 DR LAL PATHLABS LIMITED - FINANCIAL RESULTS SUMMARY Quarter & Year Ended March 31, 2026 --- HEADLINE NUMBERS • Q4 FY26 Revenue: Rs 703 Cr with 16.6 | 2026-04-30 |
| Investor presentation DR. LAL PATHLABS LIMITED – FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue FY26: Rs. 2,763 crore, up 12.2% YoY (FY25: Rs. 2,461 crore) • Q4 FY26 Re | 2026-04-30 |
| Q3 FY26 earnings call DR. LAL PATHLABS LIMITED – Q3 FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 revenue: Rs. 660 crore (10.6% YoY growth) vs Rs. 597 crore in Q3 FY25 • 9-mont | 2026-02-03 |
| Quarterly results · Q3 FY26 DR LAL PATHLABS LIMITED – FINANCIAL SUMMARY Q3 & 9-Month Results (December 31, 2025) --- HEADLINE NUMBERS • Q3 FY26 Revenue: Rs 660 Cr (up 10.6% vs | 2026-01-30 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹5 / share ex-date Jul 30, 2026 | 2026-07-30 |
| Dividend | ₹4 / share ex-date Jun 25, 2026 · record Jun 26, 2026 | 2026-06-25 |
| Dividend | ₹3.50 / share ex-date Feb 5, 2026 | 2026-02-05 |
| Bonus issue | 1 : 1 ex-date Dec 19, 2025 | 2025-12-19 |
| Dividend | ₹7 / share ex-date Nov 7, 2025 | 2025-11-07 |
| Announcement | Date |
|---|---|
| Update on acquisition of SHL Diagnostics Dr. Lal PathLabs Limited has completed the acquisition of an 80% stake in Sunshine Healthcare Limited (SHL), a healthcare company based in Ghana. The acquisition was done through the company | 2026-09-26 |
| Acquires 70% stake in SN Genelab Private Limited Dr. Lal PathLabs Limited has announced the acquisition of a 70% stake in SN Genelab Private Limited (SN Gene), a genomics diagnostics company, for up to INR 168 crores with performance-linke | 2026-09-24 |
| Wholly owned subsidiaries approve acquisition of stakes in two companies Dr. Lal PathLabs Ltd., a major Indian diagnostic company, has announced two strategic acquisitions through its wholly-owned subsidiaries: 1. **Sunshine Healthcare Limited (SHL), Ghana**: Dr | 2026-07-24 |
| Interim dividend of Rs. 5 per equity share declared Dr. Lal PathLabs Ltd., a major diagnostic laboratory company, announced an interim dividend of Rs. 5 per equity share approved by its Board of Directors on July 24, 2026. Key Details: - Int | 2026-07-24 |
| Update on acquisition of another business or stake Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates - Update on Acquisition | 2026-05-01 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dr. Lal Path Labs Ltd. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.